hotspot -WSS

hotspot

author：focus 2025-09-14 21:54:55 - browse：866

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： White House drug czar issues call for 'recovery

explore

WSS

After decades in use, heart stents finally beat placebo

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Senators: Long

Study suggests Covid rebound is far more common with Paxlovid than without

Senators: Long

knowledge

hotspot

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Experimental asthma app from Apple and Anthem shows promise

Cancer drug shortages should be causing more outrage

Healthy food access boosts outcomes in two studies

After affirmative action ruling, medical educators look to 'holistic review'

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Wildfire smoke exposes gaps in outdoor worker protections

Biotech lab space demand falls sharply

Heart attack and stroke risk calculators need revising

CDC's new outbreak response network to include Northeastern

entertainment

Ventyx halts psoriasis drug development after lackluster trial results

Readout LOUD podcast: possible new ALS drug, artificial wombs

Hearing on Medicare drug price negotiation gets unusually heated

Study suggests Covid rebound is far more common with Paxlovid than without

Study suggests Covid rebound is far more common with Paxlovid than without

STAT Virtual Event: Putting AI to the Test

hotspot

explore

leisure time

focus